Literature DB >> 16644709

Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor.

Patrice D Cani1, Claude Knauf, Miguel A Iglesias, Daniel J Drucker, Nathalie M Delzenne, Rémy Burcelin.   

Abstract

Nondigestible fermentable dietary fibers such as oligofructose (OFS) exert an antidiabetic effect and increase the secretion of glucagon-like peptide 1 (GLP-1). To determine the importance of GLP-1 receptor-dependent mechanisms for the actions of OFS, we studied high-fat-fed diabetic mice treated with OFS for 4 weeks in the presence or absence of the GLP-1 receptor antagonist exendin 9-39 (Ex-9). OFS improved glucose tolerance, fasting blood glucose, glucose-stimulated insulin secretion, and insulin-sensitive hepatic glucose production and reduced body weight gain. Ex-9 totally prevented the beneficial effects of OFS. Furthermore, GLP-1 receptor knockout mice (GLP-1R(-/-)) were completely insensitive to the antidiabetic actions of OFS. At the molecular level, the effects of OFS on endogenous glucose production correlated with changes of hepatic IRS (insulin receptor substrate)-2 and Akt phosphorylation in an Ex-9-dependent manner. As inflammation is associated with diabetes and obesity, we quantified nuclear factor-kappaB and inhibitor of kappaB kinase beta in the liver. The activity of both intracellular inflammatory effectors was reduced by OFS but, importantly, this effect could not be reverted by Ex-9. In summary, our data show that the antidiabetic actions of OFS require a functional GLP-1 receptor. These findings highlight the therapeutic potential of enhancing endogenous GLP-1 secretion for the treatment of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644709     DOI: 10.2337/db05-1360

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  121 in total

1.  Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: a randomized, placebo-controlled clinical trial.

Authors:  Parvin Dehghan; Bahram Pourghassem Gargari; Mohammad Asgharijafarabadi
Journal:  Health Promot Perspect       Date:  2013-06-30

Review 2.  Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective.

Authors:  Jun-Ling Han; Hui-Ling Lin
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 3.  Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics.

Authors:  Glenn R Gibson; Robert Hutkins; Mary Ellen Sanders; Susan L Prescott; Raylene A Reimer; Seppo J Salminen; Karen Scott; Catherine Stanton; Kelly S Swanson; Patrice D Cani; Kristin Verbeke; Gregor Reid
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-14       Impact factor: 46.802

Review 4.  Effect of inulin-type fructans on blood lipid profile and glucose level: a systematic review and meta-analysis of randomized controlled trials.

Authors:  F Liu; M Prabhakar; J Ju; H Long; H-W Zhou
Journal:  Eur J Clin Nutr       Date:  2016-09-14       Impact factor: 4.016

5.  Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia.

Authors:  P D Cani; A M Neyrinck; F Fava; C Knauf; R G Burcelin; K M Tuohy; G R Gibson; N M Delzenne
Journal:  Diabetologia       Date:  2007-09-06       Impact factor: 10.122

6.  The endocannabinoid system links gut microbiota to adipogenesis.

Authors:  Giulio G Muccioli; Damien Naslain; Fredrik Bäckhed; Christopher S Reigstad; Didier M Lambert; Nathalie M Delzenne; Patrice D Cani
Journal:  Mol Syst Biol       Date:  2010-07       Impact factor: 11.429

Review 7.  Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader
Journal:  Diabetes Care       Date:  2010-10       Impact factor: 19.112

8.  Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability.

Authors:  P D Cani; S Possemiers; T Van de Wiele; Y Guiot; A Everard; O Rottier; L Geurts; D Naslain; A Neyrinck; D M Lambert; G G Muccioli; N M Delzenne
Journal:  Gut       Date:  2009-02-24       Impact factor: 23.059

9.  Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants.

Authors:  Tamara J Nicolson; Elisa A Bellomo; Nadeeja Wijesekara; Merewyn K Loder; Jocelyn M Baldwin; Armen V Gyulkhandanyan; Vasilij Koshkin; Andrei I Tarasov; Raffaella Carzaniga; Katrin Kronenberger; Tarvinder K Taneja; Gabriela da Silva Xavier; Sarah Libert; Philippe Froguel; Raphael Scharfmann; Volodymir Stetsyuk; Philippe Ravassard; Helen Parker; Fiona M Gribble; Frank Reimann; Robert Sladek; Stephen J Hughes; Paul R V Johnson; Myriam Masseboeuf; Remy Burcelin; Stephen A Baldwin; Ming Liu; Roberto Lara-Lemus; Peter Arvan; Frans C Schuit; Michael B Wheeler; Fabrice Chimienti; Guy A Rutter
Journal:  Diabetes       Date:  2009-06-19       Impact factor: 9.461

Review 10.  The environment within: how gut microbiota may influence metabolism and body composition.

Authors:  A Vrieze; F Holleman; E G Zoetendal; W M de Vos; J B L Hoekstra; M Nieuwdorp
Journal:  Diabetologia       Date:  2010-01-26       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.